Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of PCV13a in Healthy People
NCT02544698Phase 1Unknown
- Sponsor
- Beijing Chaoyang District Center for Disease Control and Prevention
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of Prevnar 13 in pneumococcal disease (4 arms), sponsored by Beijing Chaoyang District Center for Disease Control and Prevention. Primary endpoint: Rate of adverse reactions at 3 months. Status: unknown.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT02544698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544698.